Pancreatic Cancer Research

ResearcherHarvard UniversityActive in the last 2 years

Manuel M. Hidalgo

ORCID-verified (high confidence, 0.95), identity_conf@1As of 6 November 2026

Matched on ORCID iD 0000-0002-3765-3318; OpenAlex author ID A5086660695. Sources: ClinicalTrials.gov.

Their work

Papers
80 (first author 6, last author 28)
Trials
1 (principal investigator on 1)
Grants
0
Labs led
5
Collaborators
294
Papers, trials and grants by year

2011: 9 papers · 2012: 7 papers · 2013: 10 papers · 2014: 5 papers · 2015: 7 papers · 2016: 4 papers, 1 trial · 2017: 5 papers · 2018: 6 papers · 2019: 2 papers · 2020: 5 papers · 2021: 4 papers · 2022: 5 papers · 2023: 3 papers · 2024: none · 2025: 5 papers · 2026: 3 papers

Papers 50 of 80

  1. Intravenous hyaluronidase-expressing oncolytic adenovirus with chemotherapy in metastatic pancreatic cancer: a randomized phase 2b trial. Last author DOI 10.1038/s41591-026-04705-y↗
  2. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  3. Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More. Last author DOI 10.1158/1078-0432.ccr-25-4177↗
  4. Preclinical Development of Magnetic Nanoparticles for Hyperthermia Treatment of Pancreatic Cancer. Co-author DOI 10.1021/acsami.4c16129↗
  5. A Phase III Randomized Trial of Integrated Genomics and Avatar Models for Personalized Treatment of Pancreatic Cancer: The AVATAR Trial. Last author DOI 10.1158/1078-0432.ccr-23-4026↗
  6. Non-canonical ALK7 pathways promote pancreatic cancer metastasis through β-catenin/MMP-mediated basement membrane breakdown and intravasation. Co-author DOI 10.1186/s12943-025-02384-w↗
  7. TRYBECA-1: A Randomized Phase III Study of Eryaspase Combined With Chemotherapy Versus Chemotherapy as Second-Line Treatment in Patients With Advanced Pancreat… Last author DOI 10.1200/jco-25-00872↗
  8. Sonic hedgehog inhibitor suppresses carcinoma associated fibroblasts to prime Gemcitabine/Nab-Paclitaxel and anti-CTLA4 immunotherapy as sequential first-line … Last author DOI 10.64898/2025.12.14.25342225↗
  9. Personalized tumor vaccine for pancreatic cancer. Co-author DOI 10.1007/s00262-022-03237-x↗
  10. Inhibiting NR5A2 targets stemness in pancreatic cancer by disrupting SOX2/MYC signaling and restoring chemosensitivity. Co-author DOI 10.1186/s13046-023-02883-y↗
  11. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA. Co-author DOI 10.1186/s13073-023-01171-w↗
  12. ASGE guideline on screening for pancreatic cancer in individuals with genetic susceptibility: summary and recommendations Co-author DOI 10.1016/j.gie.2021.12.001↗
  13. American Society for Gastrointestinal Endoscopy guideline on screening for pancreatic cancer in individuals with genetic susceptibility: methodology and review… Co-author DOI 10.1016/j.gie.2021.12.002↗
  14. Organoid Sensitivity Correlates with Therapeutic Response in Patients with Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-20-4116↗
  15. Facts and Hopes in Immunotherapy of Pancreatic Cancer. Last author DOI 10.1158/1078-0432.ccr-21-3452↗
  16. SOX9 Triggers Different Epithelial to Mesenchymal Transition States to Promote Pancreatic Cancer Progression. Co-author DOI 10.3390/cancers14040916↗
  17. Targeting Pin1 renders pancreatic cancer eradicable by synergizing with immunochemotherapy. Co-author DOI 10.1016/j.cell.2021.07.020↗
  18. Elevated levels of mitochondrial CoQ10 induce ROS-mediated apoptosis in pancreatic cancer. Co-author DOI 10.1038/s41598-021-84852-z↗
  19. VCN-01 disrupts pancreatic cancer stroma and exerts antitumor effects. Last author DOI 10.1136/jitc-2021-003254↗
  20. Motixafortide and Pembrolizumab Combined to Nanoliposomal Irinotecan, Fluorouracil, and Folinic Acid in Metastatic Pancreatic Cancer: The COMBAT/KEYNOTE-202 Tr… Last author DOI 10.1158/1078-0432.ccr-21-0929↗
  21. CDK4/6 Inhibitors Impair Recovery from Cytotoxic Chemotherapy in Pancreatic Adenocarcinoma. Co-author DOI 10.1016/j.ccell.2020.01.007↗
  22. From state-of-the-art treatments to novel therapies for advanced-stage pancreatic cancer. First author DOI 10.1038/s41571-019-0281-6↗
  23. BL-8040, a CXCR4 antagonist, in combination with pembrolizumab and chemotherapy for pancreatic cancer: the COMBAT trial. Last author DOI 10.1038/s41591-020-0880-x↗
  24. Lewis Antigen Phenotype and Survival of Patients With Pancreatic Cancer. Co-author DOI 10.1097/mpa.0000000000001687↗
  25. Discovery of New Targets to Control Metastasis in Pancreatic Cancer by Single-cell Transcriptomics Analysis of Circulating Tumor Cells. Last author DOI 10.1158/1535-7163.mct-19-1166↗
  26. Management and supportive treatment of frail patients with metastatic pancreatic cancer. Last author DOI 10.1016/j.jgo.2018.06.005↗
  27. Phase I/II Trial to Evaluate the Efficacy and Safety of Nanoparticle Albumin-Bound Paclitaxel in Combination With Gemcitabine in Patients With Pancreatic Cance… Last author DOI 10.1200/jco.18.00089↗
  28. Phase I/II trial of pimasertib plus gemcitabine in patients with metastatic pancreatic cancer. First author DOI 10.1002/ijc.31603↗
  29. Ruxolitinib + capecitabine in advanced/metastatic pancreatic cancer after disease progression/intolerance to first-line therapy: JANUS 1 and 2 randomized phase… Co-author DOI 10.1007/s10637-018-0580-2↗
  30. Management of unresectable, locally advanced pancreatic adenocarcinoma. Last author DOI 10.1007/s12094-017-1679-1↗
  31. Management of hyperbilirubinaemia in pancreatic cancer patients. Last author DOI 10.1016/j.ejca.2018.01.078↗
  32. Personalized RNA Medicine for Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-2733↗
  33. From First Line to Sequential Treatment in the Management of Metastatic Pancreatic Cancer. First author DOI 10.7150/jca.23716↗
  34. Consensus guidelines for diagnosis, treatment and follow-up of patients with pancreatic cancer in Spain. Co-author DOI 10.1007/s12094-016-1594-x↗
  35. Neoadjuvant treatment for borderline and resectable pancreatic ductal adenocarcinoma. Last author DOI 10.1007/s12094-017-1680-8↗
  36. Pancreatic ductal adenocarcinoma: metastatic disease. Last author DOI 10.1007/s12094-017-1690-6↗
  37. Treatment of Pancreatic Cancer Patient-Derived Xenograft Panel with Metabolic Inhibitors Reveals Efficacy of Phenformin. Co-author DOI 10.1158/1078-0432.ccr-17-1115↗
  38. A phase 2 trial of personalized cytotoxic therapy based on tumor immunohistochemistry in previously treated metastatic pancreatic cancer patients. Co-author DOI 10.21037/jgo.2017.09.05↗
  39. Preoperative treatment with gemcitabine plus nab-paclitaxel is a safe and effective chemotherapy for pancreatic adenocarcinoma. Co-author DOI 10.1016/j.ejso.2016.01.006↗
  40. Superior therapeutic efficacy of nab-paclitaxel over cremophor-based paclitaxel in locally advanced and metastatic models of human pancreatic cancer. Last author DOI 10.1038/bjc.2016.215↗
  41. SPARC-Independent Delivery of Nab-Paclitaxel without Depleting Tumor Stroma in Patient-Derived Pancreatic Cancer Xenografts. Co-author DOI 10.1158/1535-7163.mct-15-0764↗
  42. Lurbinectedin induces depletion of tumor-associated macrophages, an essential component of its in vivo synergism with gemcitabine, in pancreatic adenocarcinoma… Co-author DOI 10.1242/dmm.026369↗
  43. Addressing the challenges of pancreatic cancer: future directions for improving outcomes. Co-author DOI 10.1016/j.pan.2014.10.001↗
  44. Pancreatic cancer: from state-of-the-art treatments to promising novel therapies. First author DOI 10.1038/nrclinonc.2015.53↗
  45. The miR-17-92 cluster counteracts quiescence and chemoresistance in a distinct subpopulation of pancreatic cancer stem cells. Co-author DOI 10.1136/gutjnl-2014-308470↗
  46. Microenvironmental hCAP-18/LL-37 promotes pancreatic ductal adenocarcinoma by activating its cancer stem cell compartment. Co-author DOI 10.1136/gutjnl-2014-308935↗
  47. Therapeutic Targeting of the Warburg Effect in Pancreatic Cancer Relies on an Absence of p53 Function. Co-author DOI 10.1158/0008-5472.can-15-0108↗
  48. Inhibition of CD47 Effectively Targets Pancreatic Cancer Stem Cells via Dual Mechanisms. Co-author DOI 10.1158/1078-0432.ccr-14-1399↗
  49. SPARC Expression Did Not Predict Efficacy of nab-Paclitaxel plus Gemcitabine or Gemcitabine Alone for Metastatic Pancreatic Cancer in an Exploratory Analysis o… Co-author DOI 10.1158/1078-0432.ccr-14-3222↗
  50. Metabolomic evaluation of Mitomycin C and rapamycin in a personalized treatment of pancreatic cancer. Co-author DOI 10.1002/prp2.67↗

Trials 1

  1. Personalised Therapy for Metastatic ADPC Determined by Genetic Testing and Avatar Model Generation Principal investigator NCT02795650↗

Closest collaborators

The 25 strongest of 294 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Teresa Mercade Macarulla · 14 shared papers, 2013–2026 · strength 1.45
  2. Bruno Bockorny · 8 shared papers, 2020–2025 · strength 1.20
  3. Anirban Maitra · 15 shared papers, 2011–2026 · strength 0.91
  4. Roberto Pazo-Cid · 6 shared papers, 2017–2026 · strength 0.84
  5. Rocio García‐Carbonero · 5 shared papers, 2021–2026 · strength 0.81
  6. Senthil K. Muthuswamy · 7 shared papers, 2018–2025 · strength 0.81
  7. Carmen Guillén‐Ponce · 6 shared papers, 2017–2026 · strength 0.77
  8. Jaime Feliú · 5 shared papers, 2020–2025 · strength 0.68
  9. Francesca Sarno · 4 shared papers, 2016–2025 · strength 0.57
  10. Paul E. Oberstein · 2 shared papers, 2021–2026 · strength 0.53
  11. N.V. Rajeshkumar · 13 shared papers, 2011–2017 · strength 0.45
  12. Ling Huang · 4 shared papers, 2018–2023 · strength 0.43
  13. Peter Y. Yu · 1 shared paper, 2026 · strength 0.43
  14. Christopher Heeschen · 8 shared papers, 2011–2023 · strength 0.41
  15. Chris Nevala-Plagemann · 2 shared papers, 2020–2026 · strength 0.40
  16. Joseph Elan Grossman · 2 shared papers, 2022 · strength 0.37
  17. Ignacio Garrido‐Laguna · 5 shared papers, 2011–2020 · strength 0.36
  18. Bruno Sáinz · 6 shared papers, 2013–2023 · strength 0.35
  19. Mandeep Sawhney · 3 shared papers, 2022 · strength 0.35
  20. Mariano Ponz‐Sarvisé · 3 shared papers, 2020–2025 · strength 0.34
  21. Eric Van Cutsem · 4 shared papers, 2013–2025 · strength 0.33
  22. Eileen Mary O'Reilly · 4 shared papers, 2013–2026 · strength 0.32
  23. Talia Golan · 3 shared papers, 2020–2022 · strength 0.32
  24. Daniel D. Von Hoff · 7 shared papers, 2011–2020 · strength 0.32
  25. Rafael Álvarez-Gallego · 4 shared papers, 2017–2021 · strength 0.31

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.